Our office will work with your prescribing provider to obtain hold orders and communicate them to you before your procedure
Tambin deben evitarla quienes padecen problemas de tiroides, hipotensin o estn bajo tratamiento con anticoagulantes, ya que podra interactuar con los medicamentos y alterar su efectividad
This route however appears to be largely ignored and probably will continue to be ignored, since the strategy so far has been to simply create agonists which are structurally designed to be resistant to DPP-4 (In fact, most modifications to extend the half-life of GLP1R/GIPR/GR agonists so far, do so by making the drugs resistant to DPP-4 )
Most patients find the injection process easy and manageable with proper guidance
Patients can also purchase ancillary supplies, like syringes and needles, and will have access to important patient-friendly instructional materials on correctly administering the medicine via needle and syringe

Off-Label Use: Some medications are prescribed off-label for weight loss: Semaglutide (Ozempic): FDA-approved for type 2 diabetes (not weight loss) Identical to Wegovy but different indication Commonly prescribed off-label for weight loss Same effectiveness as Wegovy Tirzepatide (Mounjaro): FDA-approved for type 2 diabetes (not weight loss) Identical to Zepbound but different indication Prescribed off-label for weight loss before Zepbound approval Same effectiveness as Zepbound Metformin: Diabetes medication sometimes used for weight loss Produces only 1-3% weight loss Not FDA-approved for weight loss Generally not recommended as primary weight loss medication The Current State of Weight Loss Medication: Clear Winners: GLP-1 receptor agonists (especially tirzepatide and semaglutide) have become the gold standard for medical weight loss, producing results previously unattainable with medication alone